key: cord-1038006-1p2n65jl
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Thrombosis After Adenovirus-Vectored COVID-19 Vaccination: A Concern on Underlying Illness
date: 2021-11-10
journal: Clin Appl Thromb Hemost
DOI: 10.1177/10760296211060446
sha: 0b0c236a28bbb2c89c3c3e5c77ae436536c127fc
doc_id: 1038006
cord_uid: 1p2n65jl

nan

restate that although pathological finding in case with thrombotic problems after vaccination can confirm the occurrence of thrombosis, it cannot definitively conclude that vaccine directly causes problems. In a recent report, post-COVID-19 vaccination acute myocardial infarction usually occurred within 24 h postvaccination. 3 Nevertheless that report on six cases of post-COVID-19 vaccination acute myocardial infarction patients is also insufficient to make general conclusions. 3 The present case occurring at very few minutes prior to COVID-19 vaccination is a good scenario implying that "not all post COVID-19 vaccination thrombotic event is caused by the vaccination". Although this case may speculate that if some of the reported cases may mistakenly reported as vaccine adverse events, a general conclusion cannot be derived from the outcome of only one patient. While it is important to understand the rare thrombohemostatic events after COVID-19 vaccinations, it is also important to highlight that vaccinations are safe and effective and most powerful tools for the fight against COVID-19.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Concern Abut the adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Acute myocardial infarction and myocarditis following COVID-19 vaccination